🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6 results for “LEO Pharma A/S” Clear

  1. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

  2. Adtralza 150 mg solution for injection in pre-filled syringe

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 2 small molecule active

    1 trial

  3. Delgocitinib cream, Cream Vehicle

    LEO Pharma A/S

    Mild to severe palmoplantar pustulosis

    phase 2 small molecule active

    1 trial

  4. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  5. Brodalumab 70 mg, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP, without the active substance., Kyntheum 210 mg solution for injection in pre-filled syringe

    LEO Pharma A/S

    Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.

    approved small molecule active

    1 trial

  6. TRALOKINUMAB, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Atopic dermatitis and moderate-to severe atopic hand eczema

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources